-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $88

Benzinga·08/17/2026 15:59:22
Listen to the news
Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $82 to $88.